Autopsy report · NCT01199731

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

“The study was stopped due to safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 30 participants enrolled.
• Results were posted on the registry 6 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

ViiV Healthcare

Sponsor type

Industry

Conditions

Infection, Human Immunodeficiency Virus

Interventions

GSK2248761 100 mg once daily; GSK2248761 200 mg once daily; Etravirine

Participants

30

Sites

41

Countries

Belgium, Canada, Italy, Romania, United States

Trials that died the same way

• Nasal High-frequency Jet Ventilation (nHFJV) Following Extubation in Preterm Infants
  “Study stopped due to safety reasons.” (88% match in meaning)
• Stroke With Transfusions Changing to Hydroxyurea
  “The study has been stopped due to safety and futility concerns.” (88% match in meaning)
• A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
  “The study terminated for safety reasons” (83% match in meaning)
• An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
  “The study was stopped due to a non-clinical safety finding.” (82% match in meaning)
• Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
  “study was stopped for business/administrative reasons and not for patient safety concerns” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.